Literature DB >> 17261422

Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study.

Eberhard Ritz1, Maurice Laville, Rudy W Bilous, Donal O'Donoghue, Armin Scherhag, Ulrich Burger, Fernando de Alvaro.   

Abstract

BACKGROUND: Patients with diabetes and anemia are at high risk of cardiovascular disease. The Anemia CORrection in Diabetes (ACORD) Study aimed to investigate the effect of anemia correction on cardiac structure, function, and outcomes in patients with diabetes with anemia and early diabetic nephropathy.
METHODS: One hundred seventy-two patients with type 1 or 2 diabetes mellitus, mild to moderate anemia, and stage 1 to 3 chronic kidney disease were randomly assigned to attain a target hemoglobin (Hb) level of either 13 to 15 g/dL (130 to 150 g/L; group 1) or 10.5 to 11.5 g/dL (105 to 115 g/L; group 2). The primary end point was change in left ventricular mass index (LVMI). Secondary end points included echocardiographic variables, renal function, quality of life, and safety.
RESULTS: Median Hb level and LVMI were similar in groups 1 and 2 (Hb, 11.9 and 11.7 g/dL [119 and 117 g/L]; LVMI, 113.5 and 112.3 g/m(2), respectively). At study end, Hb levels were 13.5 g/dL (135 g/L) in group 1 and 12.1 g/dL (121 g/L) in group 2 (P < 0.001). No significant differences were observed in median LVMI at month 15 between study groups (group 1, 112.3 g/m(2); group 2, 116.5 g/m(2)). Multivariate analysis showed a nonsignificant decrease in LVMI (P = 0.15) in group 1 versus group 2. Anemia correction had no effect on the rate of decrease in creatinine clearance, but resulted in significantly improved quality of life in group 1 (P = 0.04). There were no clinically relevant differences in adverse events between study groups.
CONCLUSION: In patients with diabetes with mild to moderate anemia and moderate left ventricular hypertrophy, correction to an Hb target level of 13 to 15 g/dL (130 to 150 g/L) does not decrease LVMI. However, normalization of Hb level prevented an additional increase in left ventricular hypertrophy, was safe, and improved quality of life.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17261422     DOI: 10.1053/j.ajkd.2006.11.032

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  33 in total

1.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

2.  Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter?

Authors:  Luca De Nicola; Francesco Locatelli; Giuseppe Conte; Roberto Minutolo
Journal:  Drugs       Date:  2014-02       Impact factor: 9.546

Review 3.  Health-related quality of life outcomes in chronic kidney disease.

Authors:  Ritu K Soni; Steven D Weisbord; Mark L Unruh
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-03       Impact factor: 2.894

Review 4.  Use of agents stimulating erythropoiesis in digestive diseases.

Authors:  Rosario Moreno López; Beatriz Sicilia Aladrén; Fernando Gomollón García
Journal:  World J Gastroenterol       Date:  2009-10-07       Impact factor: 5.742

Review 5.  Anemia, diabetes, and chronic kidney disease.

Authors:  Uzma Mehdi; Robert D Toto
Journal:  Diabetes Care       Date:  2009-07       Impact factor: 17.152

Review 6.  Erythropoietic stress and anemia in diabetes mellitus.

Authors:  Dhruv K Singh; Peter Winocour; Ken Farrington
Journal:  Nat Rev Endocrinol       Date:  2009-04       Impact factor: 43.330

7.  Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients.

Authors:  Hideki Hirakata; Yoshiharu Tsubakihara; Fumitake Gejyo; Shinichi Nishi; Yasuhiko Iino; Yuzou Watanabe; Masashi Suzuki; Akira Saito; Takashi Akiba; Daijo Inaguma; Shunichi Fukuhara; Satoshi Morita; Michiaki Hiroe; Yoshiyuki Hada; Makoto Suzuki; Makoto Akaishi; Kazutaka Aonuma; Tadao Akizawa
Journal:  Clin Exp Nephrol       Date:  2009-09-09       Impact factor: 2.801

Review 8.  Chronic kidney disease, heart failure and anemia.

Authors:  Sean A Virani; Amit Khosla; Adeera Levin
Journal:  Can J Cardiol       Date:  2008-07       Impact factor: 5.223

9.  Associations of race and ethnicity with anemia management among patients initiating renal replacement therapy.

Authors:  Steven D Weisbord; Linda F Fried; Maria K Mor; Abby L Resnick; Paul L Kimmel; Paul M Palevsky; Michael J Fine
Journal:  J Natl Med Assoc       Date:  2007-11       Impact factor: 1.798

10.  Appropriateness of anemia management in hemodialysis patients.

Authors:  Nahla A Al-Ageel; Sinaa A Al-Aqeel; Norah O Abanmy; Jamal S Alwakeel; Alaa Sabry; Khalid A Alsaran
Journal:  Saudi Pharm J       Date:  2011-09-16       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.